222 related articles for article (PubMed ID: 35741787)
1. Hypothesis: Why Different Types of SDH Gene Variants Cause Divergent Tumor Phenotypes.
Bayley JP; Devilee P
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741787
[TBL] [Abstract][Full Text] [Related]
2.
Bayley JP; Bausch B; Jansen JC; Hensen EF; van der Tuin K; Corssmit EP; Devilee P; Neumann HP
J Med Genet; 2023 Jan; 60(1):25-32. PubMed ID: 34750193
[TBL] [Abstract][Full Text] [Related]
3. Variant type is associated with disease characteristics in SDHB, SDHC and SDHD-linked phaeochromocytoma-paraganglioma.
Bayley JP; Bausch B; Rijken JA; van Hulsteijn LT; Jansen JC; Ascher D; Pires DEV; Hes FJ; Hensen EF; Corssmit EPM; Devilee P; Neumann HPH
J Med Genet; 2020 Feb; 57(2):96-103. PubMed ID: 31492822
[TBL] [Abstract][Full Text] [Related]
4. Master regulator analysis of paragangliomas carrying SDHx, VHL, or MAML3 genetic alterations.
Smestad JA; Maher LJ
BMC Cancer; 2019 Jun; 19(1):619. PubMed ID: 31234811
[TBL] [Abstract][Full Text] [Related]
5. SDH-related pheochromocytoma and paraganglioma.
Kantorovich V; King KS; Pacak K
Best Pract Res Clin Endocrinol Metab; 2010 Jun; 24(3):415-24. PubMed ID: 20833333
[TBL] [Abstract][Full Text] [Related]
6. Model systems in SDHx-related pheochromocytoma/paraganglioma.
Takács-Vellai K; Farkas Z; Ősz F; Stewart GW
Cancer Metastasis Rev; 2021 Dec; 40(4):1177-1201. PubMed ID: 34957538
[TBL] [Abstract][Full Text] [Related]
7. Models of parent-of-origin tumorigenesis in hereditary paraganglioma.
Hoekstra AS; Devilee P; Bayley JP
Semin Cell Dev Biol; 2015 Jul; 43():117-124. PubMed ID: 26067997
[TBL] [Abstract][Full Text] [Related]
8. SDHB knockout and succinate accumulation are insufficient for tumorigenesis but dual SDHB/NF1 loss yields SDHx-like pheochromocytomas.
Armstrong N; Storey CM; Noll SE; Margulis K; Soe MH; Xu H; Yeh B; Fishbein L; Kebebew E; Howitt BE; Zare RN; Sage J; Annes JP
Cell Rep; 2022 Mar; 38(9):110453. PubMed ID: 35235785
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.
Hoekstra AS; de Graaff MA; Briaire-de Bruijn IH; Ras C; Seifar RM; van Minderhout I; Cornelisse CJ; Hogendoorn PC; Breuning MH; Suijker J; Korpershoek E; Kunst HP; Frizzell N; Devilee P; Bayley JP; Bovée JV
Oncotarget; 2015 Nov; 6(36):38777-88. PubMed ID: 26472283
[TBL] [Abstract][Full Text] [Related]
10. Succinate dehydrogenase-deficient tumors: diagnostic advances and clinical implications.
Barletta JA; Hornick JL
Adv Anat Pathol; 2012 Jul; 19(4):193-203. PubMed ID: 22692282
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma.
Hensen EF; Bayley JP
Fam Cancer; 2011 Jun; 10(2):355-63. PubMed ID: 21082267
[TBL] [Abstract][Full Text] [Related]
12. Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma.
Hadrava Vanova K; Pang Y; Krobova L; Kraus M; Nahacka Z; Boukalova S; Pack SD; Zobalova R; Zhu J; Huynh TT; Jochmanova I; Uher O; Hubackova S; Dvorakova S; Garrett TJ; Ghayee HK; Wu X; Schuster B; Knapp PE; Frysak Z; Hartmann I; Nilubol N; Cerny J; Taieb D; Rohlena J; Neuzil J; Yang C; Pacak K
J Natl Cancer Inst; 2022 Jan; 114(1):130-138. PubMed ID: 34415331
[TBL] [Abstract][Full Text] [Related]
13. Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Richter S; Gieldon L; Pang Y; Peitzsch M; Huynh T; Leton R; Viana B; Ercolino T; Mangelis A; Rapizzi E; Menschikowski M; Aust D; Kroiss M; Beuschlein F; Gudziol V; Timmers HJ; Lenders J; Mannelli M; Cascon A; Pacak K; Robledo M; Eisenhofer G; Klink B
Genet Med; 2019 Mar; 21(3):705-717. PubMed ID: 30050099
[TBL] [Abstract][Full Text] [Related]
14. Metabolic implications of hypoxia and pseudohypoxia in pheochromocytoma and paraganglioma.
Kluckova K; Tennant DA
Cell Tissue Res; 2018 May; 372(2):367-378. PubMed ID: 29450727
[TBL] [Abstract][Full Text] [Related]
15. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD.
Ricketts CJ; Forman JR; Rattenberry E; Bradshaw N; Lalloo F; Izatt L; Cole TR; Armstrong R; Kumar VK; Morrison PJ; Atkinson AB; Douglas F; Ball SG; Cook J; Srirangalingam U; Killick P; Kirby G; Aylwin S; Woodward ER; Evans DG; Hodgson SV; Murday V; Chew SL; Connell JM; Blundell TL; Macdonald F; Maher ER
Hum Mutat; 2010 Jan; 31(1):41-51. PubMed ID: 19802898
[TBL] [Abstract][Full Text] [Related]
16. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
Baysal BE; Maher ER
Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
[TBL] [Abstract][Full Text] [Related]
17. Structural and functional consequences of succinate dehydrogenase subunit B mutations.
Kim E; Rath EM; Tsang VH; Duff AP; Robinson BG; Church WB; Benn DE; Dwight T; Clifton-Bligh RJ
Endocr Relat Cancer; 2015 Jun; 22(3):387-97. PubMed ID: 25972245
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
[TBL] [Abstract][Full Text] [Related]
19. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes.
Pasini B; Stratakis CA
J Intern Med; 2009 Jul; 266(1):19-42. PubMed ID: 19522823
[TBL] [Abstract][Full Text] [Related]
20. [Succinate dehydrogenase in cancer].
Moog S; Favier J
Med Sci (Paris); 2022 Mar; 38(3):255-262. PubMed ID: 35333162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
